Acting FDA Commissioner Sharpless Offers A Familiar List Of Priorities
Many of Sharpless' priorities continue the work of his predecessor, but also are designed to make "immediate and significant impact."
You may also be interested in...
In ongoing patent litigation with Genentech, Amgen may need to reveal its counsel's advice on whether it should launch, while Genentech must produce its settlement agreements with Mylan, Celltrion, and Pfizer.
The messaging around the US FDA commissioner transition has emphasized continuity and business-as-usual. But this is still all pretty weird.
Approvals also plummeted, but US FDA remains on a record-breaking pace.